Abstract
This review provides an overall survival analysis in patients with hormone-dependent ERBB2-negative metastatic breast cancer (mBC) treated with CDK4/6 inhibitors combined with endocrine therapy (ET). The results of MONALEESA-2, 3, 7, PALOMA-2, 3, and MONARCH-2, 3 studies are provided.
The emergence of a new class of drugs, CDK4/6 inhibitors, opened the way to revise the treatment algorithm for patients with HR+/HER2- mBC. Currently, in treatment lines 1 and 2, the combination of CDK4/6 inhibitors with ET is preferable. The proven overall survival advantage in treatment lines 1 and 2, and data from an exploratory analysis subgroup, demonstrate the efficacy of ribociclib in combination with ET. The results of the studies confirm the benefits of combination therapy in routine practice to treat HR+/HER2- mBC regardless of the patient's age, menopausal status, ET variant, and disease prevalence.